Skip to main content

Share story

Robotics

Humanoid Robot Market Bulletin issued

Humanoid Robot Market Bulletin issued Image: Primary
The Humanoid Robot Market Bulletin dated Feb. 26, 2026, was issued with an update frequency of biweekly. The document focuses on Tesla plans for its Optimus robot line. Tesla Chief Executive Elon Musk plans to complete the construction of mass production lines for Optimus Gen 3 within 2026. The target is an annual output of 1 million units by year end. Considerable uncertainty remains regarding high precision application scenarios, cost structure, supply chain dependency, and production progress. The bulletin notes this is compounded by a history of missed production targets. Deployment of mass production on Optimus Gen 3 is now constituted. Tesla enters a key validation phase for its substantial AI strategies. Tesla leads the market in research and development. Commercialization and scaling for Optimus remain uncertain according to the report. The bulletin includes TrendForce views on the future development forecast of Optimus. It contains sections on market updates and related analysis in a three page format.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from TrendForce and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.